Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04584112
Title A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

triple-receptor negative breast cancer

Therapies

Atezolizumab + Cyclophosphamide + Doxorubicin + MTIG7192A + Pegfilgrastim

Atezolizumab + Cyclophosphamide + Doxorubicin + MTIG7192A + Sargramostim

Atezolizumab + MTIG7192A + Nab-paclitaxel

Atezolizumab + Cyclophosphamide + Doxorubicin + Filgrastim + MTIG7192A

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.